HealthCare Royalty


HealthCare Royalty is a leading royalty acquisition company focused on commercial or near-commercial stage biopharmaceutical products. They specialize in royalty monetization and corporate financing, providing creative capital solutions to advance biopharmaceutical innovation. With over $5 billion invested in more than 85 biopharma products, HealthCare Royalty offers non-dilutive, structured financing solutions to life sciences companies, helping them fund product launches, acquire or license products, or reinvest in R&D projects.

HealthCare Royalty

HealthCare Royalty


What We Do

HealthCare Royalty provides royalty monetization services, allowing companies to raise non-dilutive capital by selling part or all of their future royalty cash flows. This service helps companies eliminate or delay dilution and unlock shareholder value.

HealthCare Royalty offers structured credit and royalty-based financing solutions to late-stage and commercial-stage life sciences companies. These solutions provide non-dilutive funding alternatives to equity issuance, enabling companies to fund product launches and other strategic initiatives.


Industry Focus


Portfolio

Royalty Monetization Up to €185 million

#Biopharmaceutical

Senior Debt $150 million

#Biopharmaceutical

Non-Dilutive Financing Up to $100 Million

#Biopharmaceutical

Debt Financing $250 Million

#Biopharmaceutical

Limited Recourse Loan $250 Million

#Biopharmaceutical

Senior Secured Notes / Convertible Notes $20 Million

#Biopharmaceutical

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.